Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC

Belzutifan is more efficacious than everolimus in the treatment of metastatic renal cell carcinoma

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC

Combining chemotherapy with cemiplimab for advanced penile cancer may serve as a viable first-line treatment option

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma

Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC